Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SGX:T14
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SGX:T14
Price:
3.36
USD
2.44%
Market Closed
Market Cap:
$4.8B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
T
|
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SGX:T14
|
CN |
|
I
|
ImmunoGen Inc
XETRA:IMU
|
US |
|
Topchoice Medical Co Inc
SSE:600763
|
CN |
|
Jiangsu Libert Inc
SSE:605167
|
CN |
|
L
|
Linedata Services SA
SWB:LN4
|
FR |
|
EJF Investments Ltd
LSE:EJFI
|
JE |
|
Tethys Oil AB
STO:TETY
|
SE |
|
Graphite India Ltd
NSE:GRAPHITE
|
IN |
|
Darling Ingredients Inc
NYSE:DAR
|
US |
Multiples-Based Value
The Multiples-Based Value of one
T14
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 3.36 USD,
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
T14 Multiples-Based Value
LOCKED
Multiples Across Competitors
T14 Competitors Multiples
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd Competitors
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SGX:T14
|
33.9B USD | 6.3 | 9.5 | 41.7 | 41.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
829.8B USD | 12.7 | 40.2 | 27.2 | 29 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
579B USD | 6.1 | 21.6 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.3 | 11.5 | 12.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
296B USD | 4.6 | 16.2 | 10 | 12.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
228.6B CHF | 5.3 | 21.2 | 13.1 | 16.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
221.8B GBP | 5.1 | 29.4 | 16.3 | 22.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.3 | 10 | 7.4 | 8.7 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.7B USD | 2.5 | 19.8 | 7.6 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.8B USD | 2.4 | 16.7 | 7.1 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
